US health insurers embrace gene therapy

According to a recent white paper, the US-based firm plans to spread the high cost of gene therapy for its members following its 2018 acquisition of Aetna. CVS Health also plans to launch a new insurance product in March to absorb the financial risk of covering these therapies. It joins two other healthcare companies in the US developing ways to mitigate the cost of gene therapy for employees. In September last year, Cigna added a programme where members pay by month to access a feature to help pay for gene therapy. Anthem also announced it also working plans. However, it is ...